Buprenorphine was discovered in 1966 as an alternative to morphine with the potential to treat narcotic addiction. The FDA approved buprenorphine/naloxone (Suboxone) for opioid use disorder in 2002. In subsequent years, various other formulations of buprenorphine/naloxone, and subsequent generic versions, have received FDA approval. The Comprehensive Addiction and Recovery Act (CARA), signed into law in July 2016, extended the authority to prescribe buprenorphine to qualifying nurse practitioners and physician assistants. The SUPPORT for Patients and Community Act (Congress.gov,) signed into law in October 2018, further expanded buprenorphine prescribing privileges (through October 1, 2023) to qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives.